Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Biogen Idec's PLEGRIDY™ (peginterferon beta-1a) approved in the US for the treatment of multiple sclerosis
Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolomod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.
EFNS 2012
Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis.
Rituximab in paediatric onset multiple sclerosis: a case series.
FDA denies Teva Copaxone generic trials petition
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Cladribine
Mitoxantrone-induced suicidal erythrocyte death.
Receptos initiates clinical trials for S1P1 agonist program, aimed at multiple sclerosis
Glatiramer acetate during early pregnancy: A prospective cohort study.
Dynamic imaging of individual remyelination profiles in multiple sclerosis.
Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases.
Efficacy and Tolerability of BAF312 in Patients With Polymyositis
Daclizumab for relapsing remitting multiple sclerosis.
[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis.]
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model.
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.
Fingolimod is a potential novel therapy for multiple sclerosis.
Study to evaluate early glatiramer acetate treatment in delaying conversion to CDMS of subjects presenting with CIS (PreCISe)
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.
Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy.
Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's disease.

Pages